Articles scientifiques

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Année : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1980-5

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Auteurs : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Année : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Stem cell transplantation can provide durable disease control in Blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Auteurs : Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
Année : 2013
Journal : Blood
Volume : 121(3)
Pages : 440-446

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Année : 2013
Journal : Breast
Volume : 22 Suppl 2
Pages : S152-5

Liquid-Based Cytology of the Breast: Pitfalls Unrecognized before Specific Liquid-Based Cytology Training - Proposal for a Modification of the Diagnostic Criteria.

Auteurs : Feoli F, Ameye L, Van Eeckhout P, Paesmans M, Marra V, Arisio R
Année : 2013
Journal : Acta Cytol.
Volume : 57(4)
Pages : 369-76

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Auteurs : Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO
Année : 2013
Journal : Eur. J. Cancer
Volume : 49(15)
Pages : 3219-28

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.

Auteurs : Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart-Gebhart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Année : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(9)
Pages : 654-63

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Auteurs : Ganz PA, Yip CH, Gralow JR, Distelhorst SR, Albain KS, Andersen BL, Bevilacqua JL, de Azambuja E, El Saghir NS, Kaur R, McTiernan A, Partridge AH, Rowland JH, Singh-Carlson S, Vargo MM, Thompson B, Anderson BO
Année : 2013
Journal : Breast
Volume : 22(5)
Pages : 606-15

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Auteurs : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Année : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pages : 13-22

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Auteurs : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Année : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73

Thoracic oncology: annual review.

Auteurs : Sculier JP, Berghmans T, Meert AP
Année : 2013
Journal : Rev Med Brux
Volume : 34(2)
Pages : 100-11

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Année : 2013
Journal : Lancet
Volume : 382(9897)
Pages : 1021-8

Single-access laparoscopic primary and incisional prosthetic hernia repair: first 50 patients.

Auteurs : Dapri G, Bruyns J, Paesmans M, Himpens J, Cadière GB
Année : 2013
Journal : Hernia
Volume : 17(5)
Pages : 619-26

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Auteurs : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Année : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Auteurs : Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C, Offner F, Coiffier B
Année : 2013
Journal : Eur. J. Cancer
Volume : 49(4)
Pages : 904-910

An atypical presentation of bronchial adenocarcinoma.

Auteurs : Langouo Fontsa M, CsToth I, Berghmans T, Feoli F, Meert AP
Année : 2013
Journal : Rev Med Brux
Volume : 34(3)
Pages : 181-3

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Auteurs : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Année : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Auteurs : Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M
Année : 2013
Journal : Lancet Oncol
Volume : 14(8)
Pages : 760-8